These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22860628)

  • 1. MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine.
    Silberstein S
    Expert Opin Pharmacother; 2012 Sep; 13(13):1961-8. PubMed ID: 22860628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the consistency of absorption of dihydroergotamine following oral inhalation: pooled results from four clinical studies.
    Kellerman DJ; Forst A; Combs DL; Borland S; Kori S
    J Aerosol Med Pulm Drug Deliv; 2013 Oct; 26(5):297-306. PubMed ID: 23273242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
    Aurora SK; Rozen TD; Kori SH; Shrewsbury SB
    Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine.
    Aurora SK; Silberstein SD; Kori SH; Tepper SJ; Borland SW; Wang M; Dodick DW
    Headache; 2011 Apr; 51(4):507-17. PubMed ID: 21457235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine.
    Noveck RJ; Douglas PS; Chow SC; Mangum B; Kori S; Kellerman DJ
    Drug Des Devel Ther; 2013; 7():619-25. PubMed ID: 23926420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans.
    Kellerman D; Kori S; Forst A; Chang J; Febbraro S; Wutann L; Thomas T; Taylor G; Dodick D
    Cephalalgia; 2012 Jan; 32(2):150-8. PubMed ID: 22174351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics.
    Shrewsbury SB; Kori SH; Miller SD; Pedinoff A; Weinstein S
    Curr Med Res Opin; 2008 Jul; 24(7):1977-85. PubMed ID: 18534051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled drug therapy development for the treatment of migraine.
    Chua AL; Silberstein S
    Expert Opin Pharmacother; 2016 Sep; 17(13):1733-43. PubMed ID: 27416108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler.
    Shrewsbury SB; Cook RO; Taylor G; Edwards C; Ramadan NM
    Headache; 2008 Mar; 48(3):355-67. PubMed ID: 18179563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: potential mechanism.
    Cook RO; Shrewsbury SB; Ramadan NM
    Headache; 2009; 49(10):1423-34. PubMed ID: 19751370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
    Kori S; Kellerman DJ; Voloshko P; Haugen G
    Clin Ther; 2012 Sep; 34(9):1920-8. PubMed ID: 22917853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of MAP0004, orally inhaled DHE in treating migraines with and without allodynia.
    Tepper SJ; Kori SH; Borland SW; Wang MH; Hu B; Mathew NT; Silberstein SD
    Headache; 2012 Jan; 52(1):37-47. PubMed ID: 22106843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orally inhaled dihydroergotamine: a review.
    Tepper SJ
    Headache; 2013 Sep; 53 Suppl 2():43-53. PubMed ID: 24024602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is orally inhaled dihydroergotamine (DHE) equivalent in efficacy in migraine to intravenous DHE?
    Tfelt-Hansen P
    Headache; 2014 Feb; 54(2):383. PubMed ID: 24512579
    [No Abstract]   [Full Text] [Related]  

  • 15. MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments.
    Tepper SJ; Kori SH; Goadsby PJ; Winner PK; Wang MH; Silberstein SD; Cutrer FM
    Mayo Clin Proc; 2011 Oct; 86(10):948-55. PubMed ID: 21964172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine.
    Silberstein SD; Kori SH
    CNS Drugs; 2013 May; 27(5):385-94. PubMed ID: 23620146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The discovery and development of inhaled therapeutics for migraine.
    Vandenbussche N; Goadsby PJ
    Expert Opin Drug Discov; 2019 Jun; 14(6):591-599. PubMed ID: 30924698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double-blind study in healthy adults.
    Bodie S; Curran AK; Gonzalez-Nelson AC; Perry JM; Manning DC; Wasilewski MM
    Headache; 2024 Jun; 64(6):643-651. PubMed ID: 38717120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects.
    Albrecht D; Iwashima M; Dillon D; Harris S; Levy J
    Headache; 2020 Apr; 60(4):701-712. PubMed ID: 31985049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.
    Lipton RB
    Headache; 1997; 37 Suppl 1():S33-41. PubMed ID: 9009472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.